<DOC>
	<DOCNO>NCT00002032</DOCNO>
	<brief_summary>The primary objective trial : To compare safety oral rifabutin versus placebo treatment Mycobacterium avium complex ( MAC ) bacteremia AIDS patient CD4 count less equal 200 cells/mm3 . To investigate incidence MAC patient . A secondary objective compare clinical response , quality life ( Karnofsky ) , survival two group .</brief_summary>
	<brief_title>Rifabutin Therapy Prevention Mycobacterium Avium Complex ( MAC ) Bacteremia AIDS Patients With CD4 Counts = &lt; 200 : A Double-Blind , Placebo-Controlled Trial</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Bacteremia</mesh_term>
	<mesh_term>Mycobacterium Infections</mesh_term>
	<mesh_term>Mycobacterium avium-intracellulare Infection</mesh_term>
	<mesh_term>Rifabutin</mesh_term>
	<criteria>Inclusion Criteria Patients must follow : Diagnosis AIDS case define infection Mycobacterium avium complex ( MAC ) . Written informed consent . Females childbearing potential must also sign special informed consent . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Known hypersensitivity rifabutin , rifampin , rifamycins , zidovudine didanosine ( ddI ) . Previous current infection due Mycobacterium avium complex ( MAC ) disease evaluate two successive blood culture two successive stool culture take within 14 day prior study initiation . Concurrent Medication : Excluded : Antiretroviral agent zidovudine ( AZT ) . Didanosine ( ddI ) . Antimycobacterial therapy . Rifampin . Isoniazid . Clofazimine . Ethambutol . Cycloserine . Ethionamide . Amikacin . Ciprofloxacin . Streptomycin . Other investigational drug . If antimicrobial therapy require treat bacterial infection ( = &lt; 14 day ) , Adria Laboratories must contact prior initiation therapy . Patients follow excluded : Known hypersensitivity rifabutin , rifampin , rifamycins , zidovudine ( AZT ) , didanosine ( ddI ) . Previous current Mycobacterium avium complex ( MAC ) infection . Perceived patient unreliability unavailability frequent monitoring . Prior Medication : Excluded within 4 week study entry : Antiretroviral agent zidovudine ( AZT ) didanosine ( ddI ) . Antimycobacterial therapy . Rifampin . Isoniazid . Clofazimine . Ethambutol . Cycloserine . Ethionamide . Amikacin . Ciprofloxacin . Required : Zidovudine ( AZT ) . Antipneumocystis prophylactic therapy . Required least 4 week prior study entry : Zidovudine ( AZT ) didanosine ( ddI ) . Antipneumocystis prophylaxis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 1992</verification_date>
	<keyword>Rifabutin</keyword>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Mycobacterium avium-intracellulare Infection</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antitubercular Agents</keyword>
</DOC>